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ABSTRACT 
There is a growing awareness within the public and respective research communities that ‘one medicine’; the 
mutually beneficial co-study of animals and humans, could unlock great benefits for both. It is therefore timely 
to explore the types of research that could be enhanced through this approach. Our review examines the 
proposition that suitably aligned studies of spontaneous clinical osteoarthritis (OA) in dogs can provide a 
wealth of research material and understanding relevant also to human, which cannot currently be obtained 
from rodent or experimentally-induced models.  
INTRODUCTION 
Osteoarthritis (OA) is the end-destination of a heterogeneous group of disease processes and its research is 
therefore complicated. The importance of OA as a global disease and a modern major health challenge 
necessitate new research strategies. In 2005, 26.9 million US adults were estimated to have OA1 and it 
accounted for 2.4% of all years lived with disability (OARSI white paper 2016). OA is also a major disease 
burden in the dog, with an overall prevalence of 2.5% in UK veterinary primary care practice2, rising to  80% 
when over 8 years of age3. Duration estimates calculate that affected dogs suffer with OA for around 11% of 
their lifespan2. 
Intriguingly, dogs show distinct, OA type-specific epidemiological patterns, notably between different breeds, 
as well as a clear influence of body size, obesity, sex, neuter status and age2. Spontaneous canine OA is 
generally considered to bear close resemblance to human OA, in terms of anatomic similarity, disease 
heterogeneity, and progression4, appearing more informative than induced dog models. For example, changes 
in articular cartilage proteoglycans observed in slowly progressive spontaneous OA in dogs, regardless of their 
age, closely match those in human OA, and differ significantly from those seen in rapidly advancing 
experimental dog OA induced by anterior (cranial) cruciate ligament transection.5  
Humans and companion canine animals both live into old age, share many environments and activities, and 
now often receive identical disease management, such as prolonged administration of anti-inflammatory drugs 
or joint replacements. Academic veterinary medicine has also developed to a point that it can provide valuable 
biomedical research data; referral centers are now routinely equipped with magnetic resonance and 36 
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computerized tomographic imaging, arthroscopy, and have access to immunohistochemical and molecular 37 
diagnostics. They are also starting to pilot advances in the use of anti-inflammatory and pain modulating drug 38 
therapies for OA6-9. 39 
This review presents a narrative synopsis of key research relating to common forms of spontaneous dog OA 40 
and places them within a framework of OA types with human disease alignment. We overview molecular 41 
genetics, methods of disease and functional outcome assessment, pain studies, and future perspectives, in the 42 
hope of highlighting potential for collaborative efforts that will expand our knowledge of dog OA for the 43 
benefit of human and veterinary patients alike.  44 
 45 
ONE HEALTH, ONE MEDICINE & VETERINARY MEDICINE 46 
The ‘One Health’ concept, which recognizes that human health is closely connected to animal health and the 47 
environment, has ancient origins dating back to Hippocrates and Aristotle. Claude Bourgelat, a key founder of 48 
18th century veterinary medicine, advocated this intimacy, which was further emphasized by the 19th century 49 
physician  Rudolf Virchow who coined the term ‘zoonosis’ upon discovering that Trichinella spiralis in pigs 50 
caused human neurocysticercosis10. Despite historic recognition of this ideology, a culture of marked 51 
anthropocentricity emerged during the 1970s, shifting research emphasis to induced ‘experimental’ animal 52 
models.  53 
One Health approaches regained momentum following the outbreaks of highly pathogenic H5N1 avian 54 
influenza (1996) and Corona virus-associated Severe Acute Respiratory Syndrome (2003). Distinct from One 55 
Health, ‘One Medicine’ is now emerging as a holistic paradigm wherein veterinary and human medical 56 
research and clinical practice collaborate to increase their understanding of shared diseases and develop new 57 
therapies11. Companion animals represent a significant population, with ~70 million pet dogs in the USA 58 
alone12. Dogs typically live into old age, come in all shapes/sizes, from highly athletic to sedentary and 59 
overweight, and live intimately with humans. As they develop many age-related chronic diseases and co-60 
morbidities on a foreshortened timescale (breed-influenced life expectancy of around 8-12 years) that are 61 
analogous to humans, there is a growing view that developing our understanding and treatment of dog OA 62 
could lead to breakthroughs in human OA13. 63 
  64 
PROBLEMS WITH EXPERIMENTALLY-INDUCED ANIMAL MODELS OF OSTEOARTHRITIS 65 
Experimentally-induced OA models are available in many large and small species14. Undeniably, because they 66 
are small, easy to house, relatively inexpensive and genetic tractable, mouse models have contributed to 67 
advancing understanding of basic disease mechanisms. Regrettably, they have proved to be poor predicators 68 
of the efficacy or toxicity of new drugs in human trials15. Rodent model OA is usually either chemically or 69 
surgically induced. The veracity of such chemical induction with intra-articular papain or monosodium 70 
iodoacetate has however been questioned, with many concluding they have utility limited only to studies of 71 
‘joint pain’ and hence, surgical joint destabilization is most frequently employed.  72 
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Early work established the clinical, biochemical and histopathological changes induced by anterior cruciate 73 
ligament (ACL) transection in dog stifle joints (Pond-Nuki model)16,17, or medial meniscectomy in rabbits18. 74 
This heralded surgically-induced OA models in smaller genetically-tractable species. Surgical medial 75 
meniscus destabilization19, usually performed in 10-12-week old animals, is currently the most widely used 76 
model, but is by no means an ideal or ‘gold standard’. Genetic modification in mice undeniably offers the 77 
advantage of allowing single gene effects to be investigated20,21 and is used extensively; some mice, notably 78 
the STR/Ort strain, exhibit idiopathic spontaneous OA22. Whilst the value of these rapidly evolving murine 79 
OA models should not be underestimated, ‘natural’ companion animal disease may more closely reflect the 80 
complex genetic, physiological and environmental variation seen in human OA8,23, whilst reducing the 81 
numbers of animals used for research. 82 
  83 
ANALOGOUS CANINE AND HUMAN OSTEOARTHRITIC DISEASES 84 
Spontaneous slowly-progressing OA occurs in various mouse strains and guinea pigs, Syrian hamsters, dogs 85 
and non-human primates, where, in general, its histopathology and pathogenesis likely more closely resemble 86 
primary human OA24. This similarity is prominent also in dogs with complex naturally occurring traits that 87 
share co-morbidities, such as obesity, with humans. Whilst dog OA is likely more variable, takes longer to 88 
develop and thus requires larger numbers than mouse studies to achieve appropriately powered study design, 89 
this review outlines some common naturally occurring forms in order that readers may consider their suitability 90 
as models for human equivalents.   91 
 92 
Dysplastic hips  93 
Hip dysplasia is a frequent risk factor for OA in both humans and dogs25-28. It is estimated that 25-50% of 94 
idiopathic human hip OA is due to developmental dysplasia (DDH); many later needing replacement1,29,30. 95 
Canine hip dysplasia (CHD) shares pathoanatomical, biochemical and clinical features with DDH and is 96 
proposed to be the best spontaneous large animal model for DDH5,31. Both show delayed capital ossification 97 
and an underpinning continuum of instability (detected by Ortolani test), with severe forms characterized by 98 
complete subluxation (Figure 2A-C) leading to focal cartilage overload and hip OA in untreated, or 99 
undertreated children and dogs30,32-34. DDH and CHD are morphologically similar; e.g. collagenous fibrils in 100 
articular cartilage of DDH patients are sparse and disordered, closely resembling TEM observations made 35 101 
years earlier in CHD.35 Many older dogs classified with normal hip conformation at two years (~adulthood) 102 
develop OA resembling human acetabular dysplasia and secondary OA in old age36. 103 
Does CHD occur with sufficient predictability to provide a feasible model? CHD occurs with 75% prevalence 104 
in Golden Retrievers and Rottweilers37. This has heralded a need for early-stage hip laxity screening38, as in 105 
humans, and improvement programs with novel laxity measures (distraction index, University of 106 
Pennsylvania), which allow screening at four months to identify dogs highly unlikely to develop OA by three 107 
years36,39. CHD resembles DDH clinically and pathologically but progresses over a compressed timeframe, 108 
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further improving its utility as a model. Many screening programs and registries employ traditional hip 109 
extended pelvic radiography (Figure 2B, C) and some have DNA banks. This highlights an opportunity to 110 
identify genetic, epigenetic, or environmental factors common to both DDH and CDH which have phenotypic 111 
characteristics similar enough to warrant simultaneous clinical and basic research, with view to augment 112 
progress in understanding, treating and preventing dog and human hip OA secondary to hip dysplasia. Recent 113 
MRI studies have explored the role of foetal movement in determining bone shape and DDH40. Although such 114 
MRI studies are currently difficult to undertake in dogs, it does suggest the possibility of a potential ‘One 115 
Medicine’ approach to advancing research in this field by careful foetal tracking of the developmental 116 
emergence of joint incongruity in DDH and CDH.  117 
CHD and DDH treatment options consist of similar symptom management, hip reconstructions and 118 
replacement methods (Figure 2D-G). Clinical features and imaging biomarkers to identify DDH, CHD and hip 119 
OA risk at an early stage would be beneficial. Trait similarities and a truncated canine lifespan make the 120 
uncovering of common early features of end-stage hip OA likely more rapid in dogs with CHD. The dog is 121 
also an excellent model of naturally-occurring hip OA41 and human total hip replacement42,43. Dogs and 122 
humans have similar bone remodelling characteristics and both require replacement for non-responsive and 123 
debilitating end-stage disease44-46. CHD and DDH are both followed up using similar clinical and functional 124 
measures, including validated clinical questionnaires, gait analysis and accelerometer measurements, and 125 
imaging techniques43,47-49, therefore making for an ideal clinical model in which OA progression and the 126 
efficacy of novel therapies can be investigated.   127 
 128 
Ruptured cruciate ligaments  129 
Canine knees have human-like anatomy50 and have been used in several surgical OA models, including 130 
transarticular impact51, tibial osteotomy52, meniscal sectioning24, articular cartilage scarification groove 131 
model53 and ACL transection16. The progressive and predictable OA changes in the ACL transection model, 132 
in particular, are often tracked in the evaluation of new therapies54 and show molecular changes regulated by 133 
the same genes as human post-traumatic and late OA55. Features typical of human knee OA, including 134 
lameness and pain, effusion, osteophytes, cartilage erosion, synovitis, subchondral sclerosis and bone marrow 135 
lesions develop in each of these models. 136 
Human ACL rupture leads to the progressive development of significant joint OA56 and the same is true of 137 
dogs 57. Spontaneous ACL rupture is common in dogs and certain breeds are particularly predisposed58,59. 138 
Analogous ACL transection is well documented to cause inflammation with cartilage and synovial reparative 139 
responses, yet ongoing instability prompts cartilage erosion and proliferation, and subchondral bone changes, 140 
mirroring spontaneous knee OA60. Spontaneous knee OA has ~20% prevalence in some dog breeds61 and ~50% 141 
develop contralateral knee ACL rupture within one year, in commonly-affected breeds such as Labrador 142 
Retrievers62. These natural homologs of experimental ACL transection also develop early osteophytes and 143 
sclerosis57 and end-stage OA over several years63,64 (Figure 1H). It is, however, highly likely that the aetiology 144 
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of rupture differs, with spontaneous canine ACL rupture typically involving non-traumatic, progressive, prior 145 
degeneration and weakening at physiological loads 65 (Figure 1I, J).  This contrasts to the trauma-related ACL 146 
rupture in humans, which is typically a result of non-contact sporting injury66. Whilst the underlying 147 
mechanisms of the canine ligament pathology remain undefined, predisposed dogs display thinner collagen 148 
fibrils in weaker ACLs, with increased expression of matrix metalloproteinase-2 (MMP2)58. Although rupture 149 
in young human ACL is considered truly traumatic, ~70% of macroscopically normal human ACLs have 150 
histological evidence of pathology consistent with early degeneration67, questioning whether there may be 151 
greater homology than previously thought.  152 
Irrespective of the route of anterior cruciate deficiency, the resultant mechanical instability and trauma in both 153 
dogs and humans, drives progressive OA and is frequently associated meniscal pathology 68, and hence dog 154 
ACL disease/OA is an excellent model of human knee OA. Data from studies of dog knee OA show that 155 
neutering increases the risk of ACL rupture as does being female and overweight6959. It has in fact been found 156 
that estrogen reduces ACL collagen synthesis in vitro70,71 and that the risk of ACL rupture in female athletes 157 
is increased on the first and second day of their menstrual cycle72. Hence the at risk female dog may offer 158 
insight into the potential roles of hormones or post-neutering weight gain73. Primary knee OA incidence in 159 
post-menopausal females is also higher than in age-matched men, suggesting possible hormonal influences.74 160 
Additionally, the common and predictive nature of dog cruciate rupture and OA, offer unique opportunities 161 
such as rising synovial fluid concentrations of IL-8 predicting contralateral cruciate ligament failure75. It 162 
remains to be seen if these are recapitulated in humans. 163 
 164 
Osteochondrosis lesions 165 
Canine shoulders not only develop age-related primary OA76 but also most-commonly osteochondrosis, with 166 
osteochondritis dessicans lesions (OCD; Figure 1A-C)77. Osteochondrosis occurs in many animals78,79 and 167 
humans and is characterised by disordered endochondral ossification, superimposed upon previously normal 168 
growth80. This accepted pattern of pathogenesis emanates from work in pigs, but data from other species lacks 169 
consistency. The location, radiographic and macroscopic appearance of lesions in femoral and humeral 170 
condyles and trochlear talus does however point strongly to shared aetiology81. In dogs, osteochondrosis 171 
predominates in medium/large breeds, affects males more than females and is often bilateral and site-specific82. 172 
Intriguingly, human males are also more frequently affected and bilateral disease is common77,83,84.  173 
Most histological human osteochondrosis studies use samples from end-stage disease, thus limiting scope to 174 
elucidate factors influencing onset. Some, nonetheless, have shown evidence of fibrocartilage at the junction 175 
between osteochondral ossification and opposed parent bone, resembling delayed or ununited fracture tissue85. 176 
This contrasts completely with reports of absence of calcified tissues in human and animal tissues, and suggests 177 
that osteochondrosis does not originate in subchondral bone86,87. Unilateral osteochondrosis in young dogs 178 
allows for sampling of early contralateral lesions and for arthroscopic autologous or biomaterial articular 179 
resurfacing88,89. There are strong links established between aberrant re-induction of endochondral ossification 180 
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processes in both human and mouse OA articular cartilage90,91. It is therefore intriguing that the canine shoulder 181 
is targeted in this particular way, much more so than the human. Future studies might focus on the role of the 182 
mechanical environment in the canine shoulder as a stimulus for the re-induction of these aberrant 183 
endochondral-like processes.   184 
Dogs exhibit astounding, several-fold size variation and clear inter-breed divergence in growth rate and/or 185 
physeal closure at puberty. Earlier physeal closure in small breeds is consistent with more rapid growth and likely 186 
OCD predisposition. Growth plates in larger Great Dane breeds have a larger hypertrophic region and more active 187 
BMP2/BMP6 signaling than miniature breeds92, suggesting that studies of OCD may give unique insight into the 188 
role of longitudinal bone growth in this form of OA. Another possible connection emerges from studies that 189 
establish a direct linkage between genetic selection for high growth rates, failure in mechano-adaptive bone 190 
changes and predisposition to skeletal diseases, as seen in chickens93,94. Whether similar relationships persist in 191 
dogs and humans has yet to be explored.   192 
 193 
COMPARATIVE GENETICS OF OSTEOARTHRITIS IN DOG BREEDS 194 
The Victorians (1837-1901) engendered immense pressure on canine evolution. Nearly all ~400 recognised 195 
dog breeds were stringently selected to create huge intra-specific phenotypic and behavioral variation; further 196 
reinforced by rigorous Kennel Club requirements. Broad linkage disequilibrium is therefore a characteristic of 197 
many breeds due to founder events and selection bottlenecks. Many breeds are, in essence, a homolog of the 198 
rare isolated human populations much coveted by geneticists. This selection concomitantly created significant 199 
naturally occurring, polygenetic disease predilection in some breeds. Intra-specific comparison of dogs 200 
(affected vs. unaffected) offers scope to identify candidate disease genes from these polygenetic conditions. 201 
Frequently, an argument is made for comparing pure breed dogs to mongrel or crossbreeds. We would argue 202 
that the advent of designer crossbreeds such as the ubiquitous Labradoodle (Poodle x Labrador) and the 203 
difficulty of defining the source breeds in most mongrels and crossbreeds, that this type of comparison is best 204 
avoided. Instead, it is more informative to compare high disease prevalence, pure breed dogs to low prevalence 205 
pure breeds, such as Labradors vs Greyhounds for hip dysplasia or cruciate rupture. As the canine genome is 206 
sequenced95, identification of genome-wide associations with fewer markers in dog breeds than is needed in 207 
outbred human populations offers significant opportunities; a few from hip and knee that have significant 208 
potential are focused upon in the next section.  209 
 210 
Hip Dyplasia: Whilst a genetic basis of DDH is almost certain96,97 this is undisputed in CHD98. DDH occurs 211 
in 1-20/1,000 live births, across all races and predisposing factors include familial history, being first-born and 212 
breech birth position99,100. CHD frequency in different breeds varies much more markedly, reaching ~75% and, 213 
in contrast to DDH, shows no sex predilection in most breeds; female Polish Tatra Sheepdogs however have 214 
>3-fold risk over males101. This greater intra-/inter-breed variation may yet prove valuable in identifying the 215 
genetic basis of hip dysplasia. Demographics of CHD more closely mirror DDH in late onset acetabular 216 
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dysplasia101. Familial segregation studies suggest human DDH has a multifactorial genetic basis, but statistical 217 
support for this varies across populations and nationalities. It was recently reported that recurrent risk among 218 
siblings of affected families was ~10-fold greater than in controls, with high heritability (~85%)102. Dig CHD 219 
heritability estimates range from 20-60%103. Multipoint linkage and GWAS (genome wide association studies) 220 
suggest that 5-10 quantitative trait nucleotides (QTN) of modest effect, control CHD expression104. These 221 
findings are however not always replicated in different countries with different breeds105.   222 
Some 15 genes with known roles in embryonic patterning, ECM structure and remodeling, are now associated 223 
with DDH predominantly via screening for candidate polymorphisms106. Many lack replication, except CX3 224 
chemokine receptor 1 (CX3CR1, aka fractalkine, G-protein receptor) that was first identified by linkage and 225 
exome sequencing107,108 and recently a polymorphism independently linked with DDH109. CX3CR1 serves 226 
roles in mesenchymal stem cell recruitment and CX3CR1-deficient mice develop acetabular dysplasia110.  227 
Bernese Mountain dogs also possess a canine chromosome (CFA) 37 locus with significant CHD association 228 
(near FN1 gene associated with human DDH)111. Alternative CHD-associated loci identified by GWAS in UK 229 
Labrador Retrievers (>1,000), include those on CFA01 and CFA21105. Another across-breed mapping study 230 
identified a CTBP2 SNP on CFA28, linked to CHD, specifically the Norberg angle41. This and two more loci 231 
nearest TRIM2 and DPP4, were later associated with CHD by analysis of the same data by a novel iterative 232 
mixed model approach112. Intriguingly, Feldman et al. found that three patients severely affected by sporadic 233 
DDH shared an identical frameshift ZRANB1 mutation108; notable, as ZRANB1 is in the same canine linkage 234 
disequilibrium interval as the CTBP2 polymorphism on CFA2841. Similarities in DDH and CHD genetics 235 
indicate that studying CHD in these selected breeds will yield novel mechanistic insights into hip dysplasia 236 
aetiopathology in these, and potentially other species (Figure 3).  237 
Like DDH genetic studies, dog GWAS have also resisted replication across breeds and laboratories. It is well 238 
to consider that structural variants (deletions, duplications, inversions and translocations) are estimated to 239 
produce ~30% of causal variants, fine-mapped in dogs. These are often not detected using genome wide SNP 240 
arrays. In 4,200 genotyped dogs, most variants were poorly tagged by markers in a high-density mapping array 241 
of over 180,000 markers. Thus, previous canine GWAS are likely to have missed most causal variant mutations. 242 
An intronic deletion in FBN2 was associated with CHD in a linkage analysis of a direct hip laxity trait 243 
(distraction index) and also showed upregulation in samples from dysplastic dog joints113. Although there is 244 
strong evidence that the phenotype and progression of secondary OA are similar in dysplastic human and dog 245 
joints, joint genomic, transcriptomic, biomarker, and methylomic analyses are likely to be highly informative. 246 
Fresh samples can be retrieved readily from dogs undergoing joint salvage procedures and may facilitate 247 
candidate gene screening to overcome the replication barrier, as genetic links are likely to have been missed 248 
previously. Whole genome sequencing and genotype imputation is likely necessary to capture all causal 249 
mutations in canine GWAS.  250 
Legg Calve Perthes Disease (LCPD): characterized by slow femoral head destruction in children (and 251 
adolescent avascular necrosis of the femoral head (ANFH), has an ortholog in small breed dogs. Radiographs 252 
exhibit a continuum from mild disease with subchondral and epiphyseal osteolysis, to complete femoral head 253 
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obliteration (Figure 1F, G). Hip coxa plana (coxa vara and elevated femoral greater trochanter) deformity and 254 
premature OA are typical LCPD features in children and small breed dogs. Bilateral hip OA is common in 255 
human LCPD, peaks between 4-8 years of age114 and occurs ~4 times more often in boys (~1:3,000). Dogs, in 256 
contrast, show no sex predilection.  257 
LCPD and ANFH symptoms include hip pain, limping and differing limb length. Clinical signs appear in 258 
Yorkshire Terriers, Maltese, Miniature Poodles and Chihuahua during early life (~3-11 months) and peak at 259 
skeletal maturity (6-7 months). Histologic findings suggest obstructed blood supply and necrosis of the femoral 260 
capital epiphyseal bone. Vascular studies also demonstrate greater vulnerability to trauma in the femoral 261 
epiphyseal blood supply in susceptible small breed dogs when compared to non-susceptible, mixed breeds115. 262 
Interrupted blood supply and local hypoxic injury are thus common in both LCPD pathogenesis in both children 263 
and young dogs116. Human LCPD patients exhibit elevated Factor V Leiden serum levels117, polymorphisms in 264 
endothelial nitric oxide synthase118, abnormal complement and coagulation cascades, and lipid metabolism119.  265 
Whilst raised serum levels of coagulation cascade proteins were not seen in 18 LCPD-affected dogs120 it is evident 266 
that there are phenotypic, demographic, and hormonal similarities to human LCPD, including low circulating 267 
insulin-like growth factor-1 levels, reduced arterial caliber and function, and a hyperactive personality121,122 268 
(Figure 3). 269 
Familial and isolated LCPD occurs in humans123,124, with an estimated ~0.84 heritability in relatives of probands 270 
(first affected family member)125 as well as links to environmental and demographic factor(s)126. Such heritability 271 
was found in a pedigree of experimental Manchester Terriers127. Odds ratios for LCPD ranged from 4-191 in 272 
small pure breeds compared to a mixed breed population128. A COL2A1 mutation associated with LCPD in 273 
isolated human families23,129,130 has been excluded as a candidate in dogs122 and in humans with associations with 274 
apoptosis-related genes131. A major canine genetic locus with incomplete penetrance and autosomal recessive 275 
inheritance has also been proposed132. Human methylomic studies133 and others have however concluded that 276 
even familial LCPD clustering may not have a strong genetic component, since co-twin and even monozygotic 277 
twins of an affected individual have low absolute LCPD risk134. This however, does not exclude canine studies 278 
as a means of revealing common aetiopathologic pathways in non-COL2A1 associated canine and human LCPD.    279 
Anterior (Cranial) Cruciate Ligament Rupture: Non-contact rupture of human ACL has a complex etiology 280 
and >50% of operated patients have pain and secondary OA at 10-year follow-up. As in the dog, variation in 281 
outcome is influenced by age, sex, genetics, obesity, muscle strength, activity and re-injury68. Young female 282 
athletes have 3-6 fold elevated risk of ACL injury135. This doubles in those with similarly-affected relatives136 283 
and is raised further in Caucasians137, suggesting gender- and genetically-linked human determinants. Five 284 
year-old dogs consistently show degenerative microscopic and material changes in the cranial cruciate 285 
ligament (CCL human anterior equivalent) (Figure 1K). Susceptibility to CCL rupture is increased in 286 
Labradors and Golden Retrievers and their CCLs have elevated collagen turnover, decreased stiffness, and less 287 
mature collagen crosslinks than those of relatively rupture- resistant Greyhounds58. The genetics of dog CCL 288 
rupture are complex, with a 0.15-0.27 heritability in the Newfoundland which have 4 putative QTL by linkage 289 
analysis138, but non-overlapping association on CFA1, 10 and 33 by GWAS139. A case: control comparison 290 
9 
 
across four breeds, revealed SNPs key to ligament ECM composition and strength associated with CCL rupture 291 
susceptibility140. Huang et al., later reported associations on CFA7-9112 and Baker et al., on CFA24141 that 292 
reached genome wide significance for CCL rupture in Labrador Retrievers. This lack of replication is likely 293 
due to similar limitations that apply to CHD (see above).    294 
Gene polymorphisms in FBN2142, VEGFA, KDR143, COL1A1144, DCN, ACN, BGN, and LUM9, COL5A1145, 295 
and interactions between COL5A1 and COL12A1 are linked to human ACL rupture; many encoding ECM 296 
proteins and growth factors. Kim et al146 and Kaynak et al147 elegantly reviewed genetic associations with 297 
human ACL rupture and describe a COL1A1 polymorphism that replicated in several studies148-151. The former 298 
followed with a GWAS screen, which failed to unveil ACL rupture associated polymorphisms, highlighting 299 
that replication and cross-species overlap are vital in complex traits. Functional studies based on relevant 300 
temporal tissue samples that identify expression QTL which overlap with genomic QTL and, with induction 301 
of phenotype in other species  will be necessary to establish causation. (Figure 3). 302 
FUNCTIONAL OUTCOME ASSESSMENT IN OA 303 
Pain is a cardinal symptom of OA, and symptomatic management with a limited repertoire of drug groups, in 304 
particular analgesics and anti-inflammatory drugs plays a central role in veterinary152 and human treatment. 305 
This empirical and limited approach severely hampers any useful information gathering. A clear distinction 306 
between dogs and humans however, is the ability to self-report pain. Although many veterinary studies have 307 
used visual lameness and clinical pain assessments, which report only single outcome measures, force plate 308 
and radiography are most commonly used 153. This has led to objective force plate outcome measurement, 309 
becoming a common ‘gold standard’ for functional assessment in dog research. Kinetic gait analyses using 310 
force plates and pressure mats provide objective snap-shots of impairment154,155, and the size and amenable 311 
nature of dogs make them suitable for such assessments155,156.  312 
As subjective measures of pain can be readily quantified in humans, similar objective data has only had limited 313 
use157. Instead, clinical metrology instruments and a patient-centred approach to outcome assessment has 314 
become a mainstay in human OA assessment. The patient-centered approach has now been appropriated into 315 
veterinary assessments. In dogs, clinical metrology instruments or validated outcome questionnaires are also 316 
used to capture pain-related behavior over prolonged periods in home environments158, with pet owners 317 
providing proxy assessments just as parents or care-givers would159,160. Although this methodology is 318 
significantly more available than objective assessment, the proxy reporting remains an issue for their relevancy. 319 
Nonetheless, these instruments are validated, cheap and straightforward to manage and analyse, potentially 320 
expanding the ability to gain additional outcome assessments from veterinary trials. Examples include the 321 
Canine Brief Pain Inventory (CBPI) 161 that is analogous to the human Brief Pain Inventory (BPI)48,160. Such 322 
inventories, including the Liverpool OA in Dogs index162, have to: i) be valid, reliable and responsive to clinical 323 
change, ii) measure what they seek and, be validated against a gold-standard, such as force plate analysis, and 324 
iii) demonstrate reliability to generate the same outcome whenever an unchanged subject is re-assessed160. 325 
Their power in showing disturbed sleep in dogs with OA verifies their utility 163.  326 
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New miniaturised data recording technology make telemetric accelerometry or activity monitors practical in 327 
the clinical setting. These objective assessments are cheaper, less complicated than force plates and offer easier 328 
longitudinal assessments for OA interventions and disease progression156,164-166. Many other tests are useful in 329 
OA monitoring, including thermal imaging and mechanical nociceptive threshold testing167,168. Functional 330 
activity monitoring, force plate analysis, and advanced MRI are performed in dogs in a manner that mirrors 331 
human patients. Brain imaging in conscious pet dogs is also reliable and practical, with obvious potential for 332 
comparative neuroscience studies169,170.  333 
 334 
Pain models: US Food and Drug Administration (FDA) guidelines for OA drugs, devices and biological 335 
treatment are available but, as they note, pre-clinical research advances are not being translated into effective 336 
new drugs in clinical practice, leading to questions regarding the predictive utility of current animal models 337 
(http://www.fda.gov/downloads/Drugs/GuidanceCmplianceRegulatoryInformation/Guidances/ucm0338 
71577.pdf) 17115,172. Do current animal models effectively mimic OA stage, with measurable and translatable 339 
outcomes? Similarities in neurophysiology across mammals strongly suggest that pain, experienced in humans 340 
and animals is identical172. However, pain experience in OA is complicated and involves peripheral nociceptive 341 
sensitization, structural changes in joint innervation, central nervous system sensitization and neuropathic 342 
changes and a host of mediators as well as simple nociceptive input from damaged joint tissues173. Pain severity 343 
often shows poor correlation with radiographic human174 or dog OA175 or visible structural joint changes alone. 344 
New OA pain therapies thus require effective models that recapitulate OA joint changes as well as clinical 345 
symptomatology.  346 
OA pain levels are influenced by synovitis, osteochondral pathology and sensitization, not accounted for by 347 
structural radiographic change173,176. Good OA models need to reflect the natural longitudinal history of human 348 
OA and, hence, studies of spontaneous dog OA phenotypes with advanced non-invasive imaging may best 349 
resemble progression in some human OA phenotypes177,178. Semi-quantitative MRI is powerful for imaging 350 
hitherto unobserved OA processes; it is reliable, validated and has already been used in multicenter clinical 351 
trials179,180.  352 
Defined by characteristic MRI signal intensity changes, the presence, number and size of recently identified 353 
bone marrow lesions (BML) have been linked intimately with human OA pain severity181. Natural animal 354 
BML models are clearly required and their potential has now been demonstrated in studies linking BML-like 355 
structures with focal articular cartilage change and disability in the dog ACL transection model and dog CCL 356 
rupture with OA182. The search for model species for human pain needs also to carefully consider the 357 
evolutionary role of pain responses. As prey, rodents are thought to show less overt pain signs than predators, 358 
like humans and dogs. As these ‘responses’ are common end-points for measuring pain, it is pertinent that they 359 
are evolutionarily intertwined. Thus, fellow predator species, like dogs, are likely to more accurately represent 360 
human pain physiology than rodents.  361 
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Quantitative Sensory Testing (QST) has been used in laboratory settings and humans to quantify pain. QST-362 
assessed central sensitization has been demonstrated in human OA 183,184, in experimental dog OA185 and 363 
recently in spontaneous dog OA with increased mechanical and thermal allodynia186. QST efficacy has also 364 
been demonstrated in dog total hip replacements where, as in humans 187, hyperalgesia was reversed188. 365 
Clinically-affected dogs could therefore be optimal for testing anti-hyperalgesia therapies and, at the same 366 
time, realize the potential benefit. Overall, there is compelling evidence that studies in companion dogs with 367 
OA and chronic pain may reliably predict treatment efficacy in humans through randomised controlled 368 
veterinary trials (RCVTs)166,189,190. Parallel drug intervention dog studies are thus appropriate to accelerate drug 369 
trials designed to treat human pain and may speed off-license pain treatment to improve the welfare of dogs as 370 
well.  371 
 372 
A SHARED ENVIRONMENT, DIET AND OBESITY 373 
Obesity is becoming a health crisis for both humans and their pets. Thus, >40% of USA adults were obese in 374 
2015-16191 and, similarly, prevalence of dog obesity was 24% in the 1980s, rose to 41% by 200573,192 and has 375 
likely increased further. Obesity is a known risk factor for human193 and dog OA194, yet evaluating its 376 
independent influence in humans is difficult. Work with inbred experimental dog colonies, however, has 377 
clearly shown that dietary restriction reduces OA. Six week-old gender- and body weight-matched Labrador 378 
retriever pairs from closed, inbred colonies were either ‘control-fed’ (ad libitum) or ‘diet-restricted’ (75% of 379 
control-fed). Radiographic hip OA was found in 42% of control-fed dogs by 2 years (4% in diet-restricted), 380 
which increased to 52% (vs. 13%) by five and reached 83% at 15 years (50% in diet-restricted). Intriguingly, 381 
diet-restriction also increased longevity195 and weight only moderately correlated with OA severity, suggesting 382 
that other factors, related to increased food intake, exert influence196. Diet restriction also reduces severity and 383 
prevalence of shoulder76 and elbow OA197. Whilst the aetiology of obesity-related OA remains unclear, 384 
mechanical joint impact from excessive mass overloading has been proposed; this is despite the predisposition 385 
extending to hand OA in obese humans which suggests that this form of OA incitement is more systemic. A 386 
humoral role for adipose tissue in driving systemic low-grade inflammation, with increased adipokines has 387 
instead been implicated 198. Dog adipocytes have also been shown to express key adipokines and overweight 388 
dogs are commonplace, much like their owners.  389 
 390 
APPLICATIONS AND PROSPECTS 391 
There has been a growing drive to view OA not as one disease but as a syndrome encompassing heterogeneous, 392 
stratified groups of different associated populations and characteristic etiologies. This has led to a recent 393 
growth in the appreciation that new targeted therapeutic approaches might be accelerated by OA stratification, 394 
based on phenotype (or endotype), which may also lead to better alignment with preclinical animal models. 395 
We conjecture that the common dog OA types we have highlighted in this review provide models for ready 396 
alignment based upon anatomy, aetiology and pathophysiology and propose a system for their use with view 397 
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to analogous human OA (Table 1) 398 
Human disease stratification, based on phenotype has previously identified five OA subdivisions based upon 399 
joint involvement, muscle strength, obesity and psychological depression199, whilst a systematic review by 400 
Dell’Isola200 identified six groups with either central chronic pain sensitization, inflammatory, systemic 401 
metabolism, bone/cartilage remodeling, mechanical overload and minimally symptomatic OA phenotypes. 402 
Osteoarthritis Research Society International (OARSI) recommends five phenotypes based on clinical 403 
presentation criteria201 and another systematic review of knee OA identified gender, obesity and other 404 
metabolic abnormalities, cartilage damage patterns, and inflammation variables upon which distinct structural 405 
OA phenotypes might be delineated202. 406 
What are the prospects that the study of dog OA in such a One Medicine approach might therefore accelerate 407 
new developments? Currently, cancer research demonstrates the most readily adopted application of the One 408 
Medicine approach. Cancers account for >50% of dog mortalities and, like OA, its multifactorial and complex 409 
aetiology reduces the predictive value of rodent models. The Canine Comparative Oncology Genomics 410 
Consortium (National Cancer Institute, 2007) initiated an extensive, naturally-occurring canine cancer tissue 411 
bio-repository. Partnerships between veterinary/human oncologists and biologists later generated a 412 
Comparative Oncology Trials Consortium8, which rapidly revealed new facets of carcinogenesis 203,204, 413 
translated to human trials205. From the examples highlighted in this review, the authors identify four clear 414 
opportunities to take this approach forward in OA research: 415 
 1. A source of natural diseased tissue for research 416 
From the examples provided in the proposed categorization of OA types, researchers could identify a potential 417 
clinical dog syndrome and then perform studies to verify the validity of the alignment we propose (in Table 418 
1). This could, for example, involve exploring whether there are in dogs as in humans, two distinct subgroups 419 
of symptomatic knee OA patients based upon inflammatory gene expression profiles in peripheral blood 420 
leucocytes206 or whether dogs exhibit the alternative metabolic or cell senescent ‘mechanistic’ human OA 421 
phenotypes202. In addition, clinical sample retrievals such as OCD fragments, resected ruptured anterior 422 
cruciate, excised damaged meniscus, plasma or urinary or synovial fluid sampling for biomarker assessment, 423 
or resected osteoarthritic femoral heads from hip replacement procedures would facilitate greater 424 
understanding of OA mechanisms, and perhaps enhance diagnostic and prognostic criteria.  425 
It would also be possible to correlate arthroscopic, surgical and advanced imaging data with stage-specific 426 
changes in samples taken from dogs with specific OA phenotypes (Figure 1C, 1M). Examples include CCL 427 
transection and synovial fluid and serum sample analysis along with correlation with joint scores which has 428 
been performed in experimental models previously but could be evaluated in spontaneous dog OA207 with 429 
appropriate OA staging207-209 and radiographic scoring210. Compared with rodent models, in which such 430 
evaluations are not routine or even technically feasible, larger dog joints permit longitudinal study with modern 431 
imaging and tissue sampling, and potential for revealing additional insights into early and later stage OA. 432 
Indeed sampling could begin as part of a clinical trial, as soon as clinical, radiographic, CT or MRI evidence 433 
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of abnormal joint architecture is identified. For CCL rupture, dogs with unilateral CCL disease often have 434 
premonitory radiographic and clinical signs of synovial effusion. Further partial CCL tears are often associated 435 
with painful lameness in affected dogs even though instability is minimal. Measuring soluble biomarkers in 436 
biological fluids might facilitate early diagnosis or evaluation of interventions211. Getting usable samples of 437 
sufficient quantity is a practical possibility when working with large animal dog OA models (e.g. Cornell 438 
Veterinary Biobank; https://www2.vet.cornell.edu/departments/centers/cornell-veterinary-biobank).   439 
 440 
2. A means to identify the genetic underpinnings of homologous disease 441 
Inbred dogs lend themselves to genetic analysis of complex diseases; hip dysplasia, OCD and Legg Calve 442 
Perthes are excellent examples. Dogs with OA, with blood collected for routine haematology/biochemistry 443 
(for clinical management) could potentially have any residual blood directed into research. Tissues removed 444 
as part of clinical disease management could also be utilised. Making use of the broad linkage disequilibrium 445 
introduced by selective breeding with high predilection breeds versus low predilection pure breeds will help 446 
to identify candidate disease genes in these polygenetic conditions.  447 
 448 
3. An intermediary between rodent and human clinical trials with natural disease 449 
Dog OA is ideally suited for veterinary Randomised Controlled Trials (V-RCTs), because of the rigor of the 450 
functional outcome measures. Recent work comparing peak vertical force (PVF) and accelerometer data to 451 
continuously track activity at home, in spontaneous ACL disease showed excellent between-session reliability, 452 
well-aligned with locomotor activity. This indicates that PVF is a robust, reliable and reproducible non-453 
invasive tool for monitoring and assessing the effectiveness of new therapies in natural knee OA212. Such 454 
studies are free from the ethical objections associated with the use of experimental dog models and are 455 
absolutely aligned with the 3Rs agenda213. They are also cheaper and increase the possibility of biological 456 
sampling without using additional dogs. Examples demonstrating this utility include the study of anti-nerve 457 
growth factor treatment in dogs166 and humans214 and also the use of a novel anti-inflammatory agents, 458 
licofelone and doxycycline, each of which was similarly effective in spontaneous dog OA215,216 and human 459 
OA patients in Phase III trials217,218. Intra-articular hyaluronan injection in humans219 and in dogs with CHD220 460 
also showed comparable short-term symptomatic benefit without structure modifying efficacy. 461 
An example, where dog OA studies have primacy in the One Medicine approach include trials of stem cell 462 
therapy, which have advanced more rapidly in canine OA, than in humans. Allogenic mesenchymal stem cells 463 
harvested from visceral adipose dog surgical waste (from ovariectomy) have been combined with hyaluronan 464 
and injected intra-articularly into dysplastic dog elbow OA joints, with reports of reduced lameness and 465 
hyaline-type cartilage regeneration221. Measurement of PVF and vertical impulse using force platforms 466 
suggested transitory improvement in severe hip OA following intra-articular adipose-derived mesenchymal 467 
stem cell administration222. 468 
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 469 
4. Piloting of new technologies or surgical therapies 470 
A large animal with natural disease and compressed life-times has particular benefits; human scale implants 471 
and instruments can be used, such as arthroscopic treatment; therapies are piloted in a natural rather than 472 
induced disease model; and the relatively short dog lifespan allows for end of life retrieval studies. Although 473 
this may last several years (dog lifespan ~8-12 years), these durations are much longer than most, purely 474 
research, studies would entertain, and yet not be so long to be prohibitive. Total hip replacements (THR) for 475 
example, have been in veterinary clinical usage since 1976. Outcomes are good, with <20% complication rates 476 
for cementless replacement after four years42 (Figure 2G). Development of the implants for humans, including 477 
resurfacing hip replacements223, porous implants224 and hydroxyapatite coated prostheses, all relied heavily on 478 
testing in experimental dogs, and current veterinary modular hip replacements include both cemented and 479 
uncemented osseointegrative replacements. Similar complications such as aseptic loosening, bone remodeling 480 
and implant infection are seen in dogs as in humans. Post-mortem retrieval of implant material from veterinary 481 
patients, several years later is relatively cheap and easy, and could provide researchers with insights that are 482 
currently lacking. Such samples have been used to examine the mechanical, histomorphologic and 483 
radiographic features of aseptic loosening, which is a particular concern in human THR in the under 50s. These 484 
studies pointed to failure initiated by PMMA-debonding from the metal implant 225. Improved designs for new 485 
implants, if appropriately and ethically managed, could be piloted in dogs as they offer a comparatively short 486 
time-frame for retrieval when compared with a human clinical trial.  487 
Other than implants, surgical treatment of articular cartilage defects in dogs and humans has included 488 
osteochondral grafts and autologous chondrocyte implantation . Mosaicoplasty or osteochondral autologous 489 
transplantation is used in humans for full-thickness lesion repair and in dogs for treating OCD226-228.  490 
CONCLUSION 491 
This review has sought to highlight the potential benefits for dog and human health that could follow the 492 
adoption of ‘One Medicine’ approaches to basic and clinical research and practice for OA.  Human and dog 493 
OA are heterogeneous and spontaneous with many homologies, similar co-morbidities and known distinctions 494 
(Figures 2 and 3). There is much to be gained from studying a large animal with spontaneous OA, and 495 
understanding the reasons for differences may be just as informative as the similarities.  496 
A key current issue is that publication of veterinary research findings is usually restricted to veterinary-focused 497 
journals. We have consequently sought also to increase awareness of: i) V-RCTs, with a database (being 498 
developed by American Veterinary Medical Association), ii) national repositories of canine OA samples, iii) 499 
national retrieval banks for implants and, iv) clear V-RCT guidelines with standardized outcome assessments 500 
in order to allow their amalgamation into an OA ‘One Medicine’ paradigm. We emphasise that these resources 501 
have barely exploited in OA research and that their integration could generate breakthroughs in OA treatment 502 
in dogs and humans and in understanding how genetics, epigenetics, biomechanics and lifestyle impact OA 503 
aetiology and pathogenesis.  504 
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 505 
KEY POINTS 506 
 Dog OA types offer a potential stratification rationale for etiological differences and alignment to 507 
homologous human OA phenotypes 508 
 Relatively compressed time-course of spontaneous dog OA offers more ideal longitudinal research 509 
opportunities 510 
 Genetic inbreeding and dog breed OA predisposition allow for easier candidate genes identification than in 511 
outbred humans 512 
 Collaboration with veterinary researchers can provide OA samples from early stage disease  513 
 Opportunities to evaluate and translate new therapeutics into a spontaneous disease model 514 
 Comparative OA studies provide insights from different mechanical environments linked with weight-515 
bearing and non weight-bearing in quadrupedal dogs and bipedal human joints 516 
 517 
Figure 1. Canine OA locations and types.  518 
A-C. Shoulder OCD lesions in adolescent dog: (A) lateral radiograph (arrow marks the flap); (B) transverse 519 
CT and (C) arthroscopic removal.  D-E. Hip CDH: (D) Transverse  CT showing subchondral lesions and 520 
peripheral new bone formation associated with (E) OA eburnated explanted femoral head. F-G. Hip LCPD: 521 
(F) Excised femoral head with central dark line showing articular surface defect  and (G) radiograph with 522 
typical LCPD focal lucencies. H-J. Knee OA: (H) Lateral radiograph of OA canine knee with ACL rupture; 523 
(I) knee with healthy ACL and (J) spontaneously degenerate ACL (arrow shows anteriomedial band damage). 524 
K-M. Canine elbow OA: (K1-4) Anterio-posterior radiographs showing progressively increasing OA change; 525 
(L) Transverse CT of dysplastic elbow with OA and (M) Outerbridge grade III cartilage degeneration on 526 
arthroscopic examination. 527 
Figure 2. Comparative canine and human diagnostic imaging. 528 
Radiographic images of (A) dysplastic human infant luxated left hip (with permission R. Loder); (B) bilateral 529 
dysplastic and luxated hips of 3-month-old dog imaged in supine quadrupedal weight-bearing position; (C) an 530 
adult dog with severe hip dysplasia and luxoid hips imaged in a dorsolateral extended-hip position, and OA 531 
hip joints from (D) middle aged male human and (E) middle aged large breed dog, both with advanced 532 
remodeled new bone formation and sclerosis. Radiographic images of (F) a human total hip replacement, 533 
uncemented stem and cup, and (G) canine total hip replacement (cemented stem, uncemented cup). (H) T1-534 
weighted sagittal MRI of healthy canine knee. (I) Proton density turbo spin echo sequence (PD TSE) sagittal 535 
MRI human knee (Courtesy Karyn Chappell).  536 
Figure 3. Diagrammatic representation of three canine forms of OA (hip LCPD, hip CHD and knee ACL) 537 
with relationships to human homologs highlighted where applicable. Similarities to aetiopathology in canine 538 
and human OA forms of each is demonstrated.    539 
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Table 1. Proposed system for stratification of the common dog OA types with corresponding alignment 540 
to analogous human OA, based upon anatomy, aetiology and pathophysiology. * potential to classify an adult 541 
form of DDH (with acetabular dysplasia) with late onset hip OA in aged dogs that are otherwise ‘normal’ upon 542 
screening at 2 years of age. 543 
 544 
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Table 1 1073 
Canine OA Type Canine disease Canine Epidemiology Human analogy 
 
Acquired juvenile 
instability 
Hip dysplasia Juvenile large/giant breeds (prevalent in 
Retrievers, Rottweilers, German Shepherds; 
extremely rare in Greyhounds and Borzois)  
Adolescent dogs, 3-12months old* 
Progression to OA 1 year 
Developmental dysplasia of the 
hip  
 
Infants, female prevalent 
Progression to OA 30 years 
 
Acquired adult 
instability  
Anterior cruciate rupture Young adults (2 years) and older medium/large 
breeds (Rottweiler, Retrievers, Staffordshire 
Bull Terriers).  
Middle-aged to geriatric in small breeds (>6 
years, Yorkshire Terriers, West Highland White 
Terriers). 
~50% develop contralateral disease in <2 years. 
<50% with meniscal (mostly medial) pathology. 
Neutered females increased risk 
Anterior cruciate rupture and 
meniscal injuries 
 
Active adults 
 
 
 
Menstrual cycle influence 
 
Developmental 
Vascular  
Legg Calve Perthes Small breeds (Toy/Terriers – Miniature Poodles 
and West Highland White Terriers autosomal 
recessive trait. 
Adolescent  (4-11 months old) 
Adolescent avascular necrosis of 
the femoral head 
 
Developmental 
endochondral  
Shoulder OCD, knee 
OCD 
Large/giant breeds (Great Dane, Retrievers, 
Rottweilers) 
Adolescent to young adult (5 months – 1.5 years) 
Increased in males, often bilateral 
Children, adolescents, young 
adults 
 
Familiar history  
 
Increased in males often bilateral 
 
Environmental: 
obesity-related  
Elbow, hip, shoulder Any breed, notably Labrador retriever Adult 4-8 
years old  
Middle aged and older, multiple 
joints affected 
Environmental: 
athletic/trauma-
related 
Hip, elbow, hock 
(ankle), carpus, digits 
Racing Greyhound, 4-8 years old, digital 
osteoarthritis, carpal sprains leading to OA 
Athletic individuals, often 
middle aged  
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Figure 1. Canine OA locations and types.
A-C. Shoulder OCD lesions in adolescent dog: (A) lateral radiograph (arrow marks the flap); (B) transverse CT
and (C) arthroscopic removal. D-E. Hip CDH: (D) Transverse CT showing subchondral lesions and peripheral
new bone formation associated with (E) OA eburnated explanted femoral head. F-G. Hip LCPD: (F) Excised
femoral head with central dark line showing articular surface defect and (G) radiograph with typical LCPD focal
lucencies. H-J. Knee OA: (H) Lateral radiograph of OA canine knee with ACL rupture; (I) knee with healthy ACL
and (J) spontaneously degenerate ACL (arrow shows anteriomedial band damage). K-M. Canine elbow OA: (K1-
4) Anterio-posterior radiographs showing progressively increasing OA change; (L) Transverse CT of dysplastic
elbow with OA and (M) Outerbridge grade III cartilage degeneration on arthroscopic examination.
Figure 2. Comparative canine and human diagnostic imaging.
Radiographic images of (A) dysplastic human infant luxated left hip (with permission R. Loder); (B)
bilateral dysplastic and luxated hips of 3-month-old dog imaged in supine quadrupedal weight-bearing
position; (C) an adult dog with severe hip dysplasia and luxoid hips imaged in a dorsolateral extended-
hip position, and OA hip joints from (D) middle aged male human and (E) middle aged large breed dog,
both with advanced remodeled new bone formation and sclerosis. Radiographic images of (F) a human
total hip replacement, uncemented stem and cup, and (G) canine total hip replacement (cemented
stem, uncemented cup). (H) T1-weighted sagittal MRI of healthy canine knee. (I) Proton density turbo
spin echo sequence (PD TSE) sagittal MRI human knee (Courtesy Karyn Chappell).
Figure 3. Diagrammatic representation of three canine forms of OA (hip LCPD, hip CHD and knee ACL)
with relationships to human homologs highlighted where applicable. Similarities to aetiopathology in
canine and human OA forms of each is demonstrated.
